NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES
申请人:Merck & Co., Inc.
公开号:EP1399160A2
公开(公告)日:2004-03-24
EP1399160A4
申请人:——
公开号:EP1399160A4
公开(公告)日:2004-08-25
US7259157B2
申请人:——
公开号:US7259157B2
公开(公告)日:2007-08-21
[EN] NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES<br/>[FR] ANTAGONISTES DU RECEPTEUR NR2B POUR LE TRAITEMENT OU LA PREVENTION DE MIGRAINES
申请人:MERCK & CO INC
公开号:WO2002100352A2
公开(公告)日:2002-12-19
The present invention encompasses a method for treating or preventing migraines in a mammalian patient in need of such treatment or prevention comprising administering to said patient an NR2B receptor antagonist in an amount that is effective to treat or prevent migraines. The invention also encompasses the combination of an NR2B antagonist with a cyclooxygenase-2 selective inhibitor, a calcitonin gene-related peptide receptor (CGRP) ligand, a leukotriene receptor antagonist or a 5HT1B/1D agonist for the treatment or prevention of migraines.
Compounds represented by Formula (I):
1
or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.